

## Stammzellen und neuartige Zelltherapien

- 1) Dwenger, A., Straßburger, J., and Schwerdtfeger, W. Verordnung (EG) Nr. 1394/2007 über Arzneimittel für neuartige Therapien. Umsetzung in innerstaatliches Recht. Bundesgesundheitsblatt 53, 14, 2010.
- 2) Daley, G.Q. Stem cells: roadmap to the clinic. *J Clin Invest* 120, 8.
- 3) *Stem Cells: Scientific Progress and Future Research Directions*. Department of Health and Human Services, 2001.
- 4) *Regenerative Medicine*. Department of Health and Human Services, 2006.
- 5) Forsberg, E.C., and Smith-Berdan, S. Parsing the niche code: the molecular mechanisms governing hematopoietic stem cell adhesion and differentiation. *Haematologica* 94, 1477, 2009.
- 6) Holig, K., Kramer, M., Kroschinsky, F., Bornhauser, M., Mengling, T., Schmidt, A.H., Rutt, C., and Ehninger, G. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. *Blood* 114, 3757, 2009.
- 7) Bonig, H., Wundes, A., Chang, K.H., Lucas, S., and Papayannopoulou, T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. *Blood* 111, 3439, 2008.
- 8) Broxmeyer, H.E., Orschell, C.M., Clapp, D.W., Hangoc, G., Cooper, S., Plett, P.A., Liles, W.C., Li, X., Graham-Evans, B., Campbell, T.B., Calandra, G., Bridger, G., Dale, D.C., and Srour, E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J Exp Med* 201, 1307, 2005.
- 9) Bonig, H., Chudziak, D., Priestley, G., and Papayannopoulou, T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. *Exp Hematol* 37, 402, 2009.
- 10) Bonig, H., Watts, K.L., Chang, K.H., Kiem, H.P., and Papayannopoulou, T. Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. *Stem Cells* 27, 836, 2009.
- 11) Ramirez, P., Rettig, M.P., Uy, G.L., Deych, E., Holt, M.S., Ritchey, J.K., and DiPersio, J.F. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. *Blood* 114, 1340, 2009.
- 12) Flomenberg, N., Devine, S.M., DiPersio, J.F., Liesveld, J.L., McCarty, J.M., Rowley, S.D., Vesole, D.H., Badel, K., and Calandra, G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. *Blood* 106, 1867, 2005.
- 13) Calandra, G., McCarty, J., McGuirk, J., Tricot, G., Crocker, S.A., Badel, K., Grove, B., Dye, A., and Bridger, G. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. *Bone Marrow Transplant* 41, 331, 2008.
- 14) Martin-Rendon, E., Brunskill, S.J., Hyde, C.J., Stanworth, S.J., Mathur, A., and Watt, S.M. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. *Eur Heart J* 29, 1807, 2008.
- 15) Schachinger, V., Tonn, T., Dimmeler, S., and Zeiher, A.M. Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. *Nat Clin Pract Cardiovasc Med* 3 Suppl 1, S23, 2006.
- 16) Schachinger, V., Assmus, B., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Yu, J., Corti, R., Mathey, D.G., Hamm, C.W., Tonn, T., Dimmeler, S., and Zeiher, A.M. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodeling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) trial. *Eur J Heart Fail* 11, 973, 2009.
- 17) Assmus, B., Rolf, A., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Tillmanns, H., Yu, J., Corti, R., Mathey, D.G., Hamm, C.W., Suselbeck, T., Tonn, T., Dimmeler, S., Dill, T., Zeiher, A.M., and Schachinger, V. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. *Circ Heart Fail* 3, 89.
- 18) Erbs, S., Linke, A., Schachinger, V., Assmus, B., Thiele, H., Diederich, K.W., Hoffmann, C., Dimmeler, S., Tonn, T., Hambrecht, R., Zeiher, A.M., and Schuler, G. Restoration of microvascular function in the infarct-related artery by intracoronary

- transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. *Circulation* 116, 366, 2007.
- 19) Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H., Rota, M., Musso, E., Urbaneck, K., Leri, A., Kajstura, J., Nadal-Ginard, B., and Anversa, P. Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 114, 763, 2003.
  - 20) Gneocchi, M., Zhang, Z., Ni, A., and Dzau, V.J. Paracrine mechanisms in adult stem cell signaling and therapy. *Circ Res* 103, 1204, 2008.
  - 21) Seeger, F.H., Tonn, T., Krzossok, N., Zeiher, A.M., and Dimmeler, S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. *Eur Heart J* 28, 766, 2007.
  - 22) Assmus B, Tonn T, Seeger FH, Yoon CH, Leistner D, Klotsche J, Schaechinger V, Seifried E, Zeiher AM, and S, D. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. *Journal of American College of Cardiology*, in Press.
  - 23) Wöhrle, J., Merkle, N., Mailänder, V., Nusser, T., Schauwecker, P., Bommer, M., Wiesneth, M., Schrezenmeier, H., and Hombach, V. Intracoronary stem cell therapy in patients with acute myocardial infarction – A randomized, double-blind, placebo controlled trial (SCAMI). *American Heart Journal*, in press.
  - 24) Caplan, A.I. Mesenchymal stem cells. *J Orthop Res* 9, 641, 1991.
  - 25) Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., and Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. *The International Society for Cellular Therapy position statement. Cytotherapy* 8, 315, 2006.
  - 26) Sensebe, L., Krampera, M., Schrezenmeier, H., Bourin, P., and Giordano, R. Mesenchymal stem cells for clinical application. *Vox Sang*, 2009.
  - 27) Bieback, K., Schallmoser, K., Klueter, H., and Strunk, D. Clinical Protocols for the isolation and expansion of mesenchymal stromal cells. *Transfusion Medicine and Hemotherapy* 35, 286, 2008.
  - 28) Kern, S., Eichler, H., Stoeve, J., Klueter, H., and Bieback, K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 24, 1294, 2006.
  - 29) Kocaoemer, A., Kern, S., Klueter, H., and Bieback, K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. *Stem Cells* 25, 1270, 2007.
  - 30) Schmidtke-Schrezenmeier, G., Urban, M., Sharma, S., Dausend, J., Rojewski, M., Mailänder, V., Rasche, V., Landfester, K., and Schrezenmeier, H. A promising candidate for cell-labeling to allow studies on in-vivo trafficking of advanced cell therapies by Magnetic Resonance Imaging (MRI). *Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO), Mannheim, 02.-06.10.2009. Onkologie* 32 (S4): 168 (V604). 2009.